Clinical Trials
Browse actively recruiting oncology trials and apply directly. Search by cancer type, phase, or status — each listing links to the official trial record.
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Conditions
Metastatic Colorectal Cancer
Sponsor
Hoffmann-La Roche
Locations
National Cancer Center, Goyang-si, South Korea; Chonnam National University Hwasun Hospital, Jeollanam-do, South Korea; Seoul National University Bundang Hospital, Seongnam-si, South Korea; Samsung Medical Center, Seoul, South Korea; Seoul National University Hospital, Seoul, South Korea; Severance Hospital, Yonsei University Health System, Seoul, South Korea; Asan Medical Center, Seoul, South Korea; National Cheng Kung University Hospital, Tainan, Taiwan; Taipei Veterans General Hospital, Taipei, Taiwan; National Taiwan University Hospital, Zhongzheng Dist., Taiwan
NEO-NAUTILUS is a prospective, multicenter, randomized phase III clinical trial to evaluate whether omitting axillary lymph node surgery (ALND or SLNB) in clinically lymph node-negative breast cancer patients after neoadjuvant chemotherapy is non-inferior to performing SLNB in terms of 5-year disease-free survival.
Conditions
Breast Cancer, Neoadjuvant Therapy, Sentinel Lymph Node Biopsy
Sponsor
Seoul National University Hospital
Locations
Seoul National University Hopsital, Seoul, South Korea
Complete surgical resection is the standard treatment in early-stage lung cancer. However, the patients with early resected Epidermal Growth Factor Receptor(EGFR)-mutated lung cancers have high recurrence rate. The efficacy of neoadjuvant treatment by first-generation EGFR-Tyrosine Kinase Inhibitor(TKI) has been demonstrated, however, that of the third-generation EGFR-TKI(lazertinib) has not yet been fully investigated. The aim of this study is to evaluate the efficacy of neoadjuvant Lazertinib in resectable EGFR mutation-positive NSCLC and clinical application of extracellular vesicles(EVs) based BALF liquid biopsy to identify EGFR mutation without invasive tissue biopsy.
Conditions
Non Small Cell Lung Cancer
Sponsor
Konkuk University Medical Center
Locations
Konkuk University Medical Center, Seoul, South Korea
This is a Phase I, open-label study to explore the safety profile and to find the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Magicell-NK in subjects diagnosed with stage I or stage IIa colon cancer post resection from a single site in Taiwan. During this study, 3 dose levels of Magicell-NK will be tested with a 3+3 design to determine the MTD/MFD: Cohort 1, low dose (2×10\^8 cells), Cohort 2, middle dose (6×10\^8 cells), and Cohort 3, high dose (12\~18 ×10\^8 cells).
Conditions
Colon Cancer Stage I
Sponsor
Medigen Biotechnology Corporation
Locations
Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
The primary objective of this study is to analyze the 15-year cumulative incidence of advanced colorectal neoplasia and CRC-related mortality after the index colonoscopy.
Conditions
Colorectal Neoplasia, Colorectal Cancer
Sponsor
Chinese University of Hong Kong
Locations
Prince of Wales Hospital, Shatin, New Territories, Hong Kong
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven cohorts will be enrolled in parallel in this study: Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line \[1L\] PD-L1+ cohort). Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line \[2L\] CIT-naïve cohort). Cohort 3, 5, 6 and 7 will consist of participants with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative disease with one or more PIK3CA mutations. Cohort 4 will consist of participants with locally advanced or metastatic HER2+ /HER2-low disease with one or more PIK3CA mutations who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort). In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). During Stage 2, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination, provided Stage 2 is open for enrollment and all eligibility criteria are met.
Conditions
Metastatic Breast Cancer
Sponsor
Hoffmann-La Roche
Locations
National Cancer Center Clinical Trials Center / Center for Breast Cancer, Goyang-si, South Korea; Seoul National University Hospital, Seoul, South Korea; Severance Hospital, Seoul, South Korea; Asan Medical Center, Seoul, South Korea; Samsung Medical Center, Seoul, South Korea; National Cheng Kung University Hospital, Tainan, Taiwan; National Taiwan University Hospital, Taipei, Taiwan
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Conditions
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
Sponsor
Samsung Medical Center
Locations
Ji-Yeon Kim, Seoul, South Korea
This study is the first prospective, randomized phase III clinical trial designed to evaluate whether ultrahypofractionated radiotherapy is non-inferior to conventionally moderately hypofractionated radiotherapy in terms of efficacy, with acceptable toxicity, in patients who develop biochemical recurrence following radical prostatectomy. Considering the potential clinical benefits of shorter treatment duration, cost reduction, and improved patient convenience, this study is expected to provide important evidence to optimize salvage radiotherapy strategies in routine clinical practice.
Conditions
Prostate Cancer
Sponsor
Samsung Medical Center
Locations
Samsung Medical Center, Seoul, Gangnam-gu, South Korea
The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.
Conditions
Myelodysplastic Syndromes
Sponsor
Takeda
Locations
Heamto Oncology Clinic Ahmedabad Pvt. Ltd., Ahmedabad, Gujarat, India; Apollo Hospital International Ltd, Ahmedabad, Gujarat, India; Amrita Institute of Medical Sciences, Ernākulam, Kerala, India; Tata Memorial Centre, Mumbai, Maharashtra, India; All India Institute of Medical Science, New Delhi, National Capital Territory of Delhi, India; Christian Medical College, Ludhianana, Ludhiana, Punjab, India; Christian Medical College, Vellore, Tamil Nadu, India; Max Super Speciality Hospital Vaishali (A Unit Of Crosslay Remedies Ltd.), Ghaziabad, Uttar Pradesh, India; NRS Medical College and Hospital, Kolkata, West Bengal, India; Tata Medical Center, Kolkata, Kolkata, West Bengal, India
Patients scheduled for neurovascular interventions may be eligible to have their procedure done robotically.
Conditions
Stroke, Meningioma, Neurovascular Disorder
Sponsor
Navigantis Inc.
Locations
Severence Hospital, Yonsei University College of Medicine, Seoul, Korea, South Korea
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.
Conditions
Carcinoma, Non-Small-Cell Lung
Sponsor
Janssen Research & Development, LLC
Locations
Beijing Cancer Hospital of Peking University, Beijing, China; Sichuan Cancer Hospital, Cheng Du Shi, China; West China Hospital Sichuan University, Chengdu, China; Guangdong Provincial People's Hospital, Guangzhou, China; Shandong Cancer Hospital, Jinan, China; Shanghai Pulmonary Hospital, Shanghai, China; Tianjin Chest Hospital, Tianjin, China; Kyungpook National University Chilgok Hospital, Buk Gu, South Korea; Pusan National University Hospital, Busan, South Korea; Severance Hospital Yonsei University Health System, Seoul, South Korea
Claudin 18.2 is a promising therapeutic target overexpressed on the surface of gastric cancer cells. The addition of zolbetuximab, the monoclonal antibody targeting Claudin 18.2 to chemotherapy in two recent Phase 3 studies prolonged survival outcomes, indicating that Claudin 18.2 is a valid target in gastric cancer. Asan Medical Center researchers conducted a study on Claudin 18.2 expression in patients with operable gastric cancer and defined moderate to strong claudin expression in more than 75% of tumor cells as Claudin 18.2 overexpression, which was observed in 46.5% of patients with stage I-III tumors. This suggests that zolbetuximab-based treatment may be possible in patients with LAGC. Therefore, The investigator designed a prospective, multicenter, open-label, Phase Ib/II study to determine the efficacy and safety of zolbetuximab/DOS as neoadjuvant chemotherapy in patients with LAGC.
Conditions
Stomach Neoplasm, Gastric (Stomach) Cancer
Sponsor
Asan Medical Center
Locations
Asan Medical Center, Seoul, South Korea; Asan Medical Center, Seoul, South Korea
Multi-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion. Part 1 dose escalation will enroll participants aged ≥1 year to ≤30 years to determine the recommended phase 2 dose (RP2D) of asciminib when administered with low intensity chemotherapy. Part 2 dose expansion will enroll participants aged ≥1 year to ≤30 years to evaluate safety, tolerability, and efficacy of asciminib at the RP2D with the treatment regimen.
Conditions
Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Sponsor
Novartis Pharmaceuticals
Locations
Novartis Investigative Site, Taipei, Taiwan
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer. The trial consists of two phases: the dose-escalation phase (I) and the dose-expansion phase (II). Subjects will receive a weekly single dose of HCB101 IV infusion over 60 (±10) minutes on Days 1, 8, and 15 in each 21-day cycle in combination with Bevacizumab (5 mg/kg IV day 1; given every 14 days) /Cetuximab (500 mg/m2 IV day 1; given every 14 days) , and FOLFIRI/FOLFOX until unacceptable AE(s), radiographic or clinically documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study whichever occurs first.
Conditions
CRC
Sponsor
Chang Gung Memorial Hospital
Locations
Linkou Chang-Gung Memorial Hospital, Taoyuan, Taiwan
Using the Hypotension Prediction Index in patients undergoing laparoscopic colorectal surgery, including data from National Taiwan University Hospital and Taipei Veterans General Hospital
Conditions
the Duration and Severity of Intraoperative Hypotension
Sponsor
National Taiwan University Hospital
Locations
National Taiwan University Hospital and Taipei Veterans General Hospital, Taipei, Taiwan
Endoscopic submucosal dissection (ESD) is a technique that allows curative treatment of early gastrointestinal neoplasia with organ preservation. However, it is a technically demanding procedure. Tissue traction plays a vital role in facilitating the visualization of the cutting line and the submucosal vessels, which usually only relies on the hood attached to the tip of the endoscope. However, when dealing with flat or large lesions, the absence of reliable traction in ESD contributes to its technical complexity and prolongs procedure duration. Various traction devices and techniques have been developed to provide tension for the dissection plane and optimal visibility during ESD. Most of these only provide static traction from a fixed angle, thus the effect of traction diminishes when the dissection continues. In contrast to the aforementioned traction methods, magnetic traction offers the ability to externally manipulate an internal magnetic retractor, simplifying the internal workspace. The proposed magnetic retractor is composed of a detachable clip from an hemoclip is affixed to a magnetic element. By adjusting the position of the external magnetic source, the magnetic retractor automatically couples and aligns with it, enabling simultaneous dynamic directional control during the ongoing ESD operation. A novel robotic magnetic countertraction system was developed (MAG-ESD). The system consists of two sections: an external permanent magnetic source and the disposable magnetic retractor. The external permanent magnetic source is composed by a large external permanent magnet (EPM) which held by robot arm to externally control the locomotion of the magnetic retractor within patient. The disposable magnetic retractor is a consumable surgical instrument that modified from a commercial hemoclip, which has small magnets hangs on the clip legs. The design of the disposable magnetic retractor eliminates the need for endoscope withdrawal which can be inserted through the instrument channel from the handle during ESD operations, like other common instruments. In the current pilot study, the novel MAG-ESD counetrtraction system would be tested in 20 patients who undergo gastric and colonic ESD, with the aim of evaluating the system efficacy and safety.
Conditions
Early Gastric Cancer, Colon Neoplasia
Sponsor
Chinese University of Hong Kong
Locations
Department of Surgery, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong, Hong Kong
A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor
Conditions
Cancer, Solid Tumor Cancer, Biomarkers
Sponsor
Pharosgen Co.,Ltd
Locations
Asan Medical Center, Seoul, South Korea
Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.
Conditions
Lung Cancer With Central Nervous System Metastasis
Sponsor
National Taiwan University Hospital
Locations
National Taiwan University Hospital, Taipei, Taiwan
Objective: To test the efficacy of a self-determination theory-based intervention plus instant messaging to help smokers with cancer quit smoking. Hypothesis to be tested: Subjects who are allowed to choose their quit schedule and receive regular instant messaging about smoking cessation will show a significantly higher biochemically validated quit rate than those who receive only brief advice to quit immediately. Design and Subjects: An RCT will be conducted to 1448 smokers with cancer attending the outpatient clinics of five major acute care hospitals in Hong Kong for medical follow-up. Instruments: A structured questionnaire will be used to assess subjects' smoking history and demographic and clinical characteristics. EQ-5D-5L will be used to measure subjects' quality of life. Interventions: The intervention group will receive brief advice and will be invited to choose their own quit schedules (immediate or progressive) in the outpatient clinics. They will receive instant messaging about smoking cessation during the first 6-month follow-up period. The control group will receive brief advice to quit smoking immediately in the outpatient clinics, and will receive a placebo intervention during the first 6-month follow-up period. Subjects in both groups will receive leaflets on smoking cessation.
Conditions
Smoking, Cancer
Sponsor
Chinese University of Hong Kong
Locations
The Chinese University of Hong Kong, Hong Kong, Hong Kong
To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).
Conditions
Pleural Effusion, Heart Failure, Malignant Neoplasm, Fluid Overload, Hypoalbuminemia, Renal Failure, Cirrhosis, Infections
Sponsor
Chinese University of Hong Kong
Locations
Prince of Wales Hospital, Hong Kong, New Territories, Hong Kong
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Conditions
Colorectal Cancer; Lung Cancer
Sponsor
Teclison Ltd.
Locations
China Medical University Hsinchu Hospital, Hsinchu, Taiwan; Chung Shan Medical University Hospital, Taichung, Taiwan
To conduct a feasibility trial to examine the feasibility and acceptability of conducting a randomized controlled trial that evaluates the effect of the survivorship care intervention on patient-reported outcomes, defined as symptom distress and health-related quality of life.
Conditions
Cancer, Physical Symptom Distress
Sponsor
The University of Hong Kong
Locations
Center of Cancer Medicine, Queen Mary Hospital, Hong Kong, Hong Kong; JCICC, Hong Kong, Hong Kong; Queen Mary Hospital-Department of Obstetrics & Gynaecology, Hong Kong, Hong Kong; Queen Mary Hospital-Department of Oncology, Hong Kong, Hong Kong; Queen Mary Hospital-Department of Surgery, Hong Kong, Hong Kong
The study aims to compare the efficacy of different pelvic floor muscle training (PFMT) modes on improving urinary incontinence (UI) recovery in prostate cancer (PCa) patients after radical prostatectomy (RP). The methods being compared include standard PFMT (S-PFMT) , a somatosensory interactive PFMT (SI-PFMT, an enhanced PFMT) , and a standard PFMT combined with pelvic floor muscle magnetic stimulation (S-PFMT+MS). Eligible participants are randomized into either of the groups to receive different modalities of post-operative PFMT. Subjects in the S-PFMT group received traditional verbal instructions and paper-based educational materials. For the SI-PFMT group, an interactive experiential education model was adopted. First, an educational video introduced the importance and basic information of postoperative PFMT. Then, synchronized PFMT guidance through a combination of audio and video would be used. Subjects assigned to the S-PFMT+MS group, on the basis of traditional verbal and paper-based education, pelvic floor magnetic stimulation therapy was applied using a pelvic floor magnetic stimulator, operated by the same experienced rehabilitation physician. Self administered questionnaires and 1-hour pad test would be used to assess the treatment outcomes at 1, 3, and 6 months postoperatively.
Conditions
Prostate Cancer (Post Prostatectomy)
Sponsor
The University of Hong Kong
Locations
Ruijin Hospital, Shanghai, Shanghai Municipality, China; Queen Mary Hospital, Hong Kong, Hong Kong, Hong Kong
A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer
Conditions
Colon Cancer Stage III
Sponsor
Chungnam National University Hospital
Locations
Chungnam National University Hospital, Daejeon, South Korea
Gastric cancer ranks among the top ten leading causes of death in Taiwan. Radical surgery is the sole curative method for gastric cancer. However, our previous research has revealed that elderly gastric cancer patients undergoing radical surgery face a significantly elevated risk of postoperative complications. Even after gastric cancer resection, only 70% of patients receive adjuvant chemotherapy, with a particularly low likelihood among those aged ≥ 65 to undergo such treatment. With the increasing elderly population in our country, an increasing number of elderly gastric cancer patients must decide whether they can withstand radical surgery for gastric cancer and whether to undergo adjuvant chemotherapy. Therefore, increasing the rates of elderly gastric cancer patients undergoing radical surgery and adjuvant chemotherapy, as well as improving the success rate of chemotherapy, has become a critical issue. Frailty has been a frequent topic in geriatric medicine in recent years. It involves assessing multifaceted aspects of physical functioning to determine an individual's frailty status, which can help predict the likelihood of severe side effects from medical interventions. International organizations like the American Cancer Society recommend frailty assessment for all elderly cancer patients before undergoing chemotherapy and corresponding interventions to address frailty. However, there is a lack of large-scale studies on frailty assessment and its practical clinical benefits in our population. This study is a prospective, open-label, randomized clinical trial designed to investigate the impact of geriatric intervention on the tolerance of surgery/chemotherapy in patients diagnosed with gastric cancer. As part of the study protocol, all enrolled patients will undergo a comprehensive frailty assessment within a window of 7 days before initiating their first treatment, followed by tailored geriatric interventions. The primary objective of this study is to assess and compare the effects of geriatric intervention on postoperative complications, chemotherapy tolerance, treatment-related toxicity, and overall quality of life among two distinct groups: frail and non-frail patients. Our research team aims to promote widespread frailty assessment and interventions with the following objectives: 1. Reduce the probability of postoperative complications among elderly gastric cancer patients receiving surgery. 2. Enhance the tolerance and success rate of adjuvant chemotherapy for gastric cancer. These efforts ultimately aim to improve the survival prognosis of this patient group.
Conditions
Gastric Cancer
Sponsor
Chang Gung Memorial Hospital
Locations
Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taiwan
This is a two-arm, parallel-group randomized clinical trial. Routine perioperative care would be performed in volunteers with primary Hepatocellular carcinoma. The study will enroll approximately 500 volunteers to compare the progression-free or overall survival in patients undergoing elective partial hepatectomy for primary liver tumors between propofol and sevoflurane for the maintenance of anesthesia.
Conditions
Hepatocellular Carcinoma
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Locations
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of solid abdominal neoplasms. The procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic cancers. The aim of the current study is to perform a multi-center prospective study on EUS-guided radiofrequency ablation (RFA) of solid abdominal neoplasms. The hypothesis is that EUS-guided RFA is safe, feasible and effective for treating solid abdominal neoplasms.
Conditions
Digestive System Neoplasms
Sponsor
Chinese University of Hong Kong
Locations
Department of Surgery, Prince of Wales Hospital, Hong Kong, Hong Kong
Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.
Conditions
Pancreatic Cancer Non-resectable, Tumor Pancreas, Pain Cancer
Sponsor
Chinese University of Hong Kong
Locations
Prince of Wales Hospital, Hong Kong, Hong Kong, Hong Kong
Breast cancer ranks first in Taiwan's top ten gynecological cancers. Chemotherapy is a standard treatment method for colorectal cancer and breast cancer, but while destroying cancer cells, it also destroys healthy cells, resulting in side effects. Peripheral neuropathy can lead to peripheral nerve damage and decreased activity, which affects the patient's quality of life. Currently, there is no standard and effective method for treating peripheral neuropathy caused by chemotherapy. Therefore, the purpose of this study is to investigate the effect of percutaneous electrical acupoint stimulation on improving peripheral nerve symptoms in breast cancer patients undergoing chemotherapy.
Conditions
Breast Neoplasms, Chemotherapy-induced Peripheral Neuropathy
Sponsor
National Taipei University of Nursing and Health Sciences
Locations
Changhua Christian Hospital, Changhua, Changhua, Taiwan
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.
Conditions
Carcinoma, Non-Small -Cell Lung
Sponsor
Maia Biotechnology
Locations
Changhua Christian Hospital (CCH), Changhua, Taiwan; Taipei Tzu Chi Hospital, Chiayi City, Taiwan; Chang-Gung Memorial Hospital - KaoHsiung, Kaohsiung City, Taiwan; Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH), Kaohsiung City, Taiwan; Chung Shan Medical University Hospital (CSMUH), Taichung, Taiwan; Taipei Medical University Hospital (TMUH), Taipei, Taiwan; Tri-Service General Hospital, Taipei, Taiwan; Chang-Gung Memorial Hospital - Linko, Taoyuan City, Taiwan
This study is a multicenter randomized controlled clinical trial targeting subjects with advanced or metastatic squamous NSCLC with unknown or negative gene status, aiming to evaluate the efficacy and safety of first-line delayed administration of Serplulimab combined with a low-dose Nab-Paclitaxel doublet chemotherapy regimen.
Conditions
NSCLC
Sponsor
People's Hospital of Quzhou
Locations
Quzhou people's Hospital, Quzhou, Zhejiang, China
This is an open-label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and efficacy of MG2512 injection in participants with advanced solid tumors.
Conditions
Advanced Solid Tumor
Sponsor
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Locations
Peking Union Medical College Hospital, Beijing, Beijing Municipality, China; Sichuan Cancer Hospital, Chengdu, Sichuan, China
This open-label Phase Ib study will evaluate the safety, tolerability, and preliminary effectiveness of IN10018 in combination with dalpiciclib in adults with progressive meningiomas. Progressive meningiomas are tumors arising from the membranes surrounding the brain that have continued to grow or have returned after previous treatment. Participants will receive both study drugs by mouth in 28-day treatment cycles. IN10018 will be taken once daily throughout each cycle, and dalpiciclib will be taken once daily for 21 days followed by 7 days without dalpiciclib. Treatment may continue until the tumor progresses, unacceptable side effects occur, or another reason for stopping treatment applies. The study includes a dose-confirmation phase and a dose-expansion phase. The main goals are to evaluate side effects and determine a recommended dose of the combination for further study. Researchers will also assess whether the treatment can shrink tumors or delay tumor growth, measure how the drugs are processed in the body, and explore tumor and blood biomarkers that may be associated with treatment response.
Conditions
Meningioma, CDK4/6 Inhibitor
Sponsor
Capital Medical University
Locations
Beijing Sanbo Brain Hospital, Capital Medical University, Beijing, Beijing Municipality, China; Sanbo Brain Hospital, Capital Medical University, Beijing, China
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
Conditions
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Sponsor
Taiho Oncology, Inc.
Locations
Queen Mary Hospital, Pok Fu Lam, Hong Kong Island, Hong Kong; Aichi Cancer Center, Nagoya, Aichi-ken, Japan; National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan; NHO Kyushu Cancer Center, Fukuoka, Hukuoka, Japan; Sendai Kousei Hospital, Sendai, Miyagi, Japan; Niigata Cancer Center Hospital, Niigata, Niigata, Japan; Kindai University Hospital, Sayama, Osaka, Japan; Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan; National Cancer Center Hospital, Chuo Ku, Tokyo, Japan; Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
Conditions
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Sponsor
Merck Sharp & Dohme LLC
Locations
Beijing Cancer hospital-Digestive Oncology ( Site 0061), Beijing, Beijing Municipality, China; The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 0063), Fuzhou, Fujian, China; Wuhan Union Hospital Cancer Center. ( Site 0064), Wuhan, Hubei, China; Hunan Cancer Hospital-intervention department ( Site 0066), Changsha, Hunan, China; Renji Hospital Shanghai Jiao Tong University School of Medicine-Oncology Department ( Site 0067), Shanghai, Shanghai Municipality, China; West China Hospital, Sichuan University ( Site 0068), Chengdu, Sichuan, China; National Cancer Center Hospital East ( Site 0121), Kashiwa, Chiba, Japan; Kanagawa Cancer Center ( Site 0122), Yokohama, Kanagawa, Japan; Seoul National University Hospital ( Site 0161), Seoul, South Korea; Severance Hospital, Yonsei University Health System ( Site 0164), Seoul, South Korea
This study is a prospective, single arm, phase II clinical trial. We plan to include 36 newly diagnosed ES-SCLC patients who meet the inclusion criteria and receive induction therapy (tislelizumab+EP regimen, 4-6 cycles). After completing the induction therapy, efficacy evaluation will be conducted. Patients with remission will receive tislelizumab combined with consolidation chest radiotherapy (TRT) sequentially. After the consolidation therapy is completed, they will receive tislelizumab maintenance therapy until disease progression, intolerable toxicity, or withdrawal of informed consent occurs, whichever occurs first. The treatment duration will not exceed 2 years.
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sponsor
Chongqing University Cancer Hospital
Locations
Chongqing University Affiliated Cancer Hospital, Chongqing, Chongqing Municipality, China
Primary liver cancer is one of the common malignant tumors in China, of which hepatocellular carcinoma (HCC) accounts for 85%-90%. It is worth noting that the recurrence rate of liver cancer is greater than 10% at 1 year after surgery, while the recurrence rate in 5 years reaches 70-80%. Stereotactic body radiation therapy (SBRT) refers to a kind of radiotherapy technology to achieve a steep dose gradient and achieve high-precision position and high-dose fractionated irradiation. The rapid dose drop-down enables SBRT to maximize the protection of normal tissues around the tumor, and it often requires only 1-5 times of high-dose fractionated irradiation to complete the course of treatment.SBRT may play an important role in the treatment of small intrahepatic recurrence HCC, but there is still a lack of evidence of high-level prospective studies. We intend to conduct a single-center, prospective, clinical study to further elaborate the efficacy and safety of SBRT in the treatment of small intrahepatic recurrent HCC.
Conditions
Carcinoma; Hepatocellular
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Locations
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC with KRAS and/or BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Sponsor
Institut de Recherches Internationales Servier
Locations
Beijing Cancer Hospital, Beijing, China; Shandong Cancer Hospital (Cancer Hospital of Shandong First Medical University), Jinan, China; Fudan University Zhongshan Hospital, Shanghai, China; The Second Affiliated Hospital of Soochow University, Suzhou, China; Queen Mary Hospital, Hong Kong, Hong Kong; Prince of Wales, Shatin, Hong Kong; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University Hospital, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan
The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer. The study will focus on recurrent liver cancer patients and compare participants to primary liver cancer patients as controls. The primary purpose is to assess whether the elevated levels of this protein can be used to monitor the recurrence of liver cancer. The main questions it aims to answer are: Is the levels of the protein significantly elevated in recurrent liver cancer patients compared to primary liver cancer patients? Can the protein be used as a reliable biomarker for the early detection of liver cancer recurrence? Researchers will compare the protein levels in the following groups: 50 recurrent liver cancer patients (training set) with abnormally high levels of the protein. 250 recurrent liver cancer patients (validation set) to confirm the protein's elevation in a separate cohort. Participants will be required to: * Provide blood samples for protein analysis. * Undergo regular follow-up visits for monitoring and data collection. * Allow access to their medical records for relevant clinical information.
Conditions
Recurrent Liver Cancer, Primary Liver Cancer
Sponsor
Nanjing Medical University
Locations
The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
This is an investigator-initiated, prospective, national multi-center, phase III, randomized, open-label, non-inferiority clinical study. The hypothesis is that using online adaptive radiotherapy technology for moderately fractionated radiotherapy in post-operative patients with cervical/endometrial cancer may reduce radiotherapy-related toxicity and improve quality of life while ensuring target coverage. The objective is to evaluate treatment-related toxicity and efficacy of moderately fractionated online adaptive radiotherapy compared to conventionally fractionated intensity-modulated radiotherapy in post-operative cervical and endometrial cancer patients, aiming to provide a more precise, convenient, and cost-effective treatment option for patients.
Conditions
Cervical Cancer, Endometrial Cancer
Sponsor
Xiaorong Hou
Locations
Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
This study aims to evaluate the impact of goal-oriented albumin infusion on short-term postoperative outcomes in gastric cancer patients. It is a single-center, prospective, non-randomized controlled study. Patients are divided into two groups: the experimental group receives albumin infusion when serum albumin levels fall below 25 g/L, while the control group receives albumin infusion when levels fall below 30 g/L. The primary endpoint is the incidence of complications graded Clavien-Dindo III or above within 30 days post-surgery. Secondary endpoints include nutritional recovery, gastrointestinal function recovery, hospital stay duration, and overall complication rates. The study seeks to optimize perioperative albumin management strategies and improve clinical outcomes.
Conditions
Postoperative Hypoalbuminemia, Postoperative Complications, Gastric Cancer
Sponsor
The First Hospital of Jilin University
Locations
First Hospital of Jilin University, Changchun, Jilin, China
Surgical resection remains the primary treatment for rectal cancer, but the postoperative incidence of anastomotic leakage (AL) is relatively high. AL not only increases the medical burden on patients, prolongs hospital stays, raises the need for secondary surgery, and elevates perioperative mortality, but also increases the long-term risk of local recurrence and reduces survival rates. There is an urgent need for a simple, effective treatment method that minimizes the burden on patients to prevent anastomotic leakage. The preoperative placement of a transanal drainage tube (TDT) is believed to effectively drain gas and feces from the intestinal lumen, thereby reducing intestinal pressure and alleviating tension at the anastomotic site, thus preventing AL. Previous studies have shown that traditional drainage tubes cannot effectively prevent leakage. Given the limitations of existing research on traditional TDTs, we plan to use a modified TDT (which allows postoperative irrigation and utilizes a balloon to block feces from adversely affecting the anastomosis) to conduct a randomized, parallel-controlled trial. This study aims to further investigate the role of the modified TDT in preventing and treating anastomotic leakage following rectal surgery
Conditions
Anastomotic Leak
Sponsor
Third Military Medical University
Locations
Army Medical Center (Daping Hospital), Yuzhong, Chongqing Municipality, China
This study is a single-center, single-arm, prospective, phase II clinical trial designed to evaluate the efficacy and safety of Cidabenamine combined with Azacitidine as maintenance therapy following allogeneic peripheral blood hematopoietic stem cell transplantation in patients with high-risk peripheral T-cell lymphoma.During the screening/baseline period, informed consent will be obtained, and inclusion/exclusion criteria will be verified. The study plans to enroll 40 patients in each group. Enrolled patients will undergo demographic and medical history data collection, along with assessments including vital signs, physical examination, PET-CT, bone marrow aspiration smear, flow cytometry, lymphoid gene rearrangement, and bone marrow pathology.
Conditions
Peripheral T Cell Lymphoma
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Locations
Shanghai General hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
The goal of this clinical trial is to learn to compare the safety and efficacy of virtual ileostomy versus diverting ileostomy in patients undergoing sphincter-saving surgery for rectal cancer. The main questions it aims to answer are: * Is the virtual ileostomy a safe and effective alternative to the ileostomy? * Is it scientifically reasonable to perform diverting ileostomy intraoperatively? Researchers will compare virtual ileostomy to diverting ileostomy to see if the virtual ileostomy works to reduce rates of stoma. Participants will: * Performing diverting ileostomy or virtual ileostomy undergoing sphincter-saving surgery for rectal cancer * Continuous follow-up of their complications after the first surgery
Conditions
Rectal Cancer
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Locations
Daping Hospital, Third Military Medical University, Chongqing, China
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Sponsor
Xynomic Pharmaceuticals, Inc.
Locations
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; China-Japan Friendship Hospital, Beijing, China; Peking University Third Hospital, Beijing, China; West China Hospital, Sichuan University, Chengdu, China; The First Affiliate Hospital of Dalian Medical University, Dalian, China; Fujian Medical University Union Hospital, Fuzhou, China; Fujian Provincial Cancer Hospital, Fuzhou, China; Cancer Center of Guangzhou Medical University, Guangzhou, China; Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University, Guangzhou, China; Zhejiang Cancer Hospital, Hangzhou, China
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
Conditions
HER2 Positive or Suspicious Positive Tumors
Sponsor
Peking University Cancer Hospital & Institute
Locations
uEXPLORER total-body PET/CT scanner (United Imaging, China), Beijing, China
This is a single-arm, open-label study of safety, tolerability, and anti-cancer activity of SN301A (an off-the-shelf CAR NK cell therapy) in patients with glypican-3 (GPC3)-positive advanced hepatocellular carcinoma.
Conditions
Hepatocellular Carcinoma (HCC)
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Locations
Shanghai General Hospital, Shanghai, Shanghai Municipality, China
During surgery, peritoneal metastasis is typically confirmed pathologically through resection sample. However, this process can be time-consuming when utilizing intro-operative frozen section pathology. To address this issue, we propose utilizing confocal laser endomicroscopy to provide in situ, real-time, and in-vivo diagnosis of suspected peritoneal nodules as cancer metastasis during surgery.
Conditions
Colorectal Cancer
Sponsor
Nanfang Hospital, Southern Medical University
Locations
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant radiation therapy in improving local-regional control and facilitating surgical conversion in patients with inoperable locally advanced breast cancer after 2-6 courses of neoadjuvant chemotherapy. This study will also investigate whether beta-alanine supplementation and spatially fractionated radiotherapy can enhance the therapeutic response to neoadjuvant chemoradiotherapy. In addition, this study aims to explore tumor microenvironmental features and molecular biomarkers associated with treatment response, radioresistance, immune activation, and long-term outcomes.
Conditions
Breast Neoplasms
Sponsor
Fudan University
Locations
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy. Clinical, imaging, and pathological data from previously treated patients will be collected and analyzed. The model is expected to assist in predicting treatment outcomes and guide personalized therapeutic strategies.
Conditions
Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
Sponsor
Tongji Hospital
Locations
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Page 1 of 56 · Showing 1–50 of 2,785
Trial availability and eligibility are determined by the sponsoring institution. Applying does not guarantee enrolment. Always consult your oncologist before applying.